ArticleJournal of nanobiotechnology2026
M1 macrophage-derived migrasomes exacerbate post-myocardial infarction injury via guanylate binding protein 5.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Myocardial infarction (MI) is a complex pathological process characterized by vascular injury, myocardial necrosis, and dynamic immune interactions. Migrasomes are recently identified organelles generated during cell migration, serving as key mediators of intercellular communication. However, the contribution of migrasomes to immune-mediated myocardial injury remains largely unexplored. This study demonstrated an increase in migrasome production following MI. Migrasomes can be produced by macrophages, and M1 macrophage-derived migrasomes (M1-Migs) were particularly found to exacerbate myocardial tissue injury. Quantitative proteomic sequencing demonstrated increased levels of guanylate binding protein 5 (GBP5) within M1-Migs. Viral knockdown experiments demonstrated that M1-Migs mediate their deleterious effects predominantly via GBP5. Pathway enrichment analysis further indicated that GBP5 activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling, thereby promoting myocardial cell apoptosis. Analysis of clinical samples has also demonstrated a positive correlation between macrophage-derived migrasomes and MI. Notably, colchicine may mitigate post-infarction myocardial injury by suppressing migrasome production by M1 macrophages. Overall, these findings identify macrophage-derived migrasomes as key amplifiers of myocardial injury, providing potential therapeutic targets for MI and may provide additional evidence for the clinical application of colchicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.